| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers I > Headlines for Immunicon Corp. > News item |
Immunicon, Pfizer expand clinical research, development agreement
By Lisa Kerner
Erie, Pa., March 28 - Immunicon Corp. announced an extension of its research and development agreement with Pfizer, Inc. to develop reagents designed to detect certain undisclosed antigens on circulating tumor cells (CTCs).
Both companies can begin clinical research studies by adding new appendices to the agreement, which began in February 2003, according to a company news release.
A phase 1 trial already has been added to the agreement, with enrollment to begin immediately.
"We are very pleased to expand our collaboration with Pfizer, one of the world's premier pharmaceutical companies," president and chief executive officer Byron Hewett said in the release.
"As the developer of the instrument and reagents for rare cell detection, Immunicon offers pharmaceutical and biotechnology companies a unique advantage compared to reference labs and clinical research organizations."
Immunicon develops assays and kits that are specifically paired with targeted treatments. The company also offers testing services to validate these assays in clinical trials with kits, reagents and instrument configurations that may not be commercially available, officials said.
Hewett added that by working with Pfizer, other pharmaceutical companies and the Food and Drug Administration, Immunicon hopes to establish CTCs as a standard biomarker in oncology drug development.
Pfizer is an international pharmaceutical company with headquarters in New York.
Immunicon develops and commercializes proprietary cell- and molecular-based human diagnostic and life science research products. The company is located in Huntingdon Valley, Pa.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.